🧾 What This Document Is

This is an 8-K filing from OS Therapies Inc. (OSTX). It's a current report that companies must file with the SEC to announce major events. This specific filing includes two attached agreements that together announce one big event: the company is raising money by selling stock and warrants to investors.

👉 In simple terms: OS Therapies is selling pieces of ownership (stock) and "discount coupons" for future stock (warrants) to fund its business. They hired an investment bank (Ceros) to help find buyers.

🏢 What The Company Does

OS Therapies is a clinical-stage biopharmaceutical company. They're focused on developing therapies for serious diseases, specifically in oncology (cancer treatment). This is a high-risk, high-reward business that requires significant capital to fund research and clinical trials before any product can generate revenue.

👉 Think of them as a startup in the medicine world, working on promising but unproven treatments. This fundraising is essential fuel for their research engine.

💰 The Deal & Financial Highlights

This is a registered direct offering. The company is selling securities directly to investors using an already-effective registration statement (Form S-3). Here are the key terms:

What's Being Sold: A combination of:
1. Shares of Common Stock
2. Pre-Funded Warrants: These are like IOUs for stock. Investors buy them now but can "pre-fund" (pay for) the shares later. They're used if an investor wants to avoid crossing a certain ownership percentage.
3. Common Warrants: These give investors the right to buy more common stock in the future at a set price.
Price: The purchase price is $1.40 per share. The Pre-Funded Warrants are priced at $1.399 each ($1.40 minus a nominal $0.001).
Purpose: The net proceeds will be used for general corporate purposes, which for a biotech like OS Therapies almost certainly means funding clinical trials and continuing research.

🤝 The Deal Mechanics & Costs

Who's Running the Show: Ceros Financial Services, Inc. is acting as the exclusive Placement Agent. Their job is to find investors for this deal on a "best efforts" basis—they'll try hard, but don't guarantee they'll sell all the shares.

What It Costs the Company (Compensation to Ceros):

Cash Fee: 7.00% of the total gross money raised.
Expense Reimbursement: Up to $70,000 for accountable legal fees + $20,000 for non-accountable expenses.
Warrants: Ceros will also receive warrants to buy 5% of the total shares sold in the offering. Their exercise price will be 110% of the price paid by the main investors ($1.54).

Key Restrictions on the Company: After this deal, the company agrees not to issue more stock for a period:

90 days with some exceptions.
180 days for certain types of complex financing deals called "Variable Rate Transactions."

📦 What the Company Promised (Representations)

The company made a long list of standard promises to reassure investors, including:

It is properly organized and has the authority to do this deal.
Its financial statements are accurate (based on its SEC filings).
There are no major hidden lawsuits or environmental problems.
It owns its intellectual property (its patents and research).
Its securities are not subject to unexpected preemptive rights.

⚖️ Big Picture: Strengths & Risks

👍 Strengths / Positives:

Funding Secured: This provides immediate cash to advance their clinical programs.
Established Process: Using an S-3 registration makes the process faster and simpler than a brand-new offering.
Investor Interest: Completing the deal shows there is some market appetite for their story.

⚠️ Risks & Considerations:

Dilution: This sale creates new shares, which dilutes (reduces) the ownership percentage of existing shareholders.
Warrant Overhang: The warrants (held by both investors and Ceros) represent potential future dilution if they are exercised.
High Cost: The 7% fee plus warrant kicker is a significant cost of raising this capital.
Speculative Nature: The company's value is tied almost entirely to the success of its future clinical trials, which are inherently uncertain.

🔮 What's Next

Closing: The deal is expected to close very soon (by the first business day after March 31, 2026).
Deployment of Capital: The funds will be used to advance the company's clinical trials and pipeline.
Watch the Pipeline: Future news flow will be driven by clinical trial patient enrollment, data readouts, and interactions with regulators like the FDA.

🧠 The Analogy

Imagine OS Therapies is a startup building a very expensive, complex prototype for a new kind of engine. They've run out of their own money. To keep building, they go to wealthy investors and say: "Give us money now, and in return, we'll give you a tiny piece of ownership in the whole company, plus a special coupon that lets you buy another piece later at a fixed price." This filing is the detailed contract for that transaction.

📇 Key Contacts & People

For OS Therapies Incorporated:

Paul A. Romness, MPH - President and Chief Executive Officer
Address: 115 Pullman Crossing Road, Suite #103, Grasonville, Maryland 21638
Email: [email protected]

For the Placement Agent (Ceros Financial Services, Inc.):

Mark Goldwasser - Chief Executive Officer
Address: 1445 Research Boulevard, Rockville, MD 20850
Email: [email protected]

🧩 Final Takeaway

OS Therapies, a clinical-stage biotech, has secured funding through a stock and warrant offering facilitated by Ceros Financial. While this provides critical cash for research, it comes at a cost of future dilution and highlights the company's ongoing need for capital to advance its unproven medical therapies.

OS Therapies Inc — 8-K Filing